BOC-D-FMK
Based on 10 publication(s) in Google Scholar
Boc-D-FMK is a cell-permeable, irreversible and broad spectrum caspase inhibitor. Boc-D-FMK inhibits apoptosis stimulated by TNF-α with an IC50 of 39 μM.
For research use only. We do not sell to patients.
- Purity: 95.0%
- CAS No.: 634911-80-1
- Formula: C11H18FNO5
- Molecular Weight:263.26
-
Storage:Pure form -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
Publications Citing Use of MedChemExpress (MCE) BOC-D-FMK
More- Sci Immunol. 2024 Jun 14;9(96):eadj5465. [Abstract]
- J Exp Clin Cancer Res. 2023 Jun 6;42(1):142. [Abstract]
- Adv Sci (Weinh). 2026 May;13(25):e15367. [Abstract]
- Adv Sci (Weinh). 2025 Dec 5:e20444. [Abstract]
- Anal Chem. 2017 Sep 19;89(18):9788-9796. [Abstract]
- Sci Rep. 2017 Jun 7;7(1):2929. [Abstract]
- FASEB J. 2025 Nov 30;39(22):e71250. [Abstract]
- FASEB J. 2025 Aug 31;39(16):e70901. [Abstract]
- Exp Cell Res. 2018 Sep 1;370(1):103-115. [Abstract]
- Saudi J Biol Sci. 2022 Apr;29(4):2323-2328. [Abstract]
-
WB
-
WB
All Caspase Isoforms
More
Biological Activity
|
Caspase |
Apoptosis is a pathway of cell death orchestrated by a family of proteases called caspases. Boc-D-fmk inhibits TNFα-stimulated reactive oxygen species (ROS) generation. Boc-D-FMK inhibits apoptosis stimulated by TNF-α with an IC50 of 39 μM[1]. BocD-fmk at 50 μM prevents genistein-induced apoptosis of p815 cells. Confocal microscopy shows that the release of mitochondrial apoptotic factors is inhibited by BocD-fmk[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 634911-80-1
-
Appearance <31.2°C Solid,>31.2°C Liquid
-
Molecular Weight 263.26
-
Formula C11H18FNO5
-
Color Light yellow to yellow
-
SMILES
O=C(CC(C(CF)=O)NC(OC(C)(C)C)=O)OC
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Pure form -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Publications (10)
-
Journal Impact Factor
-
Most Recent
-
Sci Immunol
Schlafen 11 triggers innate immune responses through its ribonuclease activity upon detection of single-stranded DNA. [Abstract]2024 Jun 14;9(96):eadj5465. PMID: 38875319 -
J Exp Clin Cancer Res
Ferroptosis inducers enhanced cuproptosis induced by copper ionophores in primary liver cancer. [Abstract]2023 Jun 6;42(1):142. PMID: 37277863 -
Adv Sci (Weinh)
Cuproptosis and Disulfidptosis Converge to Empower PD-L1 Checkpoint Therapy via Cadict-Induced PD-L1 Translation. [Abstract]2026 May;13(25):e15367. PMID: 41722054 -
Adv Sci (Weinh)
NADH-Reductive Stress Induced by Dihydrolipoamide Dehydrogenase Activation Contributes to Cuproptosis. [Abstract]2025 Dec 5:e20444. PMID: 41346305 -
Anal Chem
Determination of Caspase-3 Activity and Its Inhibition Constant by Combination of Fluorescence Correlation Spectroscopy with a Microwell Chip. [Abstract]2017 Sep 19;89(18):9788-9796. PMID: 28806521 -
Sci Rep
ω-3 free fatty acids and all-trans retinoic acid synergistically induce growth inhibition of three subtypes of breast cancer cell lines. [Abstract]2017 Jun 7;7(1):2929. PMID: 28592877
BOC-D-FMK purchased from MedChemExpress. Usage Cited in: Sci Rep. 2017 Jun 7;7(1):2929. [Abstract]
Caspase signaling pathway. MCF7 and MDA-MB-231 cells are pretreated with 10 µM Z-VAD-FMK and BOC-D-FMK for 1 h and then exposed to 80 μM ω3-FFAs and 20 μM ATRA for 48 h. The expression of PARP protein.
-
FASEB J
Elesclomol-Induced Copper Influx Attenuates Lung Adenocarcinoma Progression With Involvement of the ER Stress/PCK2 Axis. [Abstract]2025 Nov 30;39(22):e71250. PMID: 41251612 -
FASEB J
AKT2/mTOR/VEGF Signaling Attenuates Aging-Related Male Infertility by Suppressing Epididymal Autophagy and Apoptosis via Extracellular Vesicle-Mediated Sperm Rescue. [Abstract]2025 Aug 31;39(16):e70901. PMID: 40810376 -
Exp Cell Res
2018 Sep 1;370(1):103-115. PMID: 29908160
BOC-D-FMK purchased from MedChemExpress. Usage Cited in: Exp Cell Res. 2018 Sep 1;370(1):103-115. [Abstract]
Representative Western blots show the change of truncated tau in cells transfected with wild type human tau, followed by treatment with 1 μM Stau for 10hr, and interference with Boc-D-FMK by addition 2 hr prior to the addition Stau.
-
Saudi J Biol Sci
2022 Apr;29(4):2323-2328. PMID: 35531147
Solvent & Solubility
DMSO : 100 mg/mL (379.85 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (9.50 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (9.50 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Protocol
Rats: Boc-D-FMK is dissolved in DMSO. Male Sprague-Dawley rats group 1 (OBBOC-D) undergo common bile duct ligation and simultaneously treatment with Boc-D-FMK. The first dose of Boc-D-FMK (1.5 mg/kg) is injected into the inferior vena cava immediately after bile duct ligation. Subsequent doses of Boc-DFMK (1.5 mg/kg twice daily) are given intraperitoneally on the first and second postoperative days. The last dose (1.5 mg/kg) is given on the morning of the third postoperative day[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Purity & Documentation
-
Data Sheet (275 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Handling Instructions (2659 KB)
References
[1]. Cowburn AS, et al. z-VAD-fmk augmentation of TNF alpha-stimulated neutrophil apoptosis is compound specific and does not involve the generation of reactive oxygen species. [Content Brief]
[2]. Yee SB, et al. zVAD-fmk, unlike BocD-fmk, does not inhibit caspase-6 acting on 14-3-3/Bad pathway in apoptosis of p815 mastocytoma cells. Exp Mol Med. 2006 Dec 31;38(6):634-42. [Content Brief]
[3]. Sheen-Chen SM, et al. Effect of Boc-D-Fmk on hepatocyte apoptosis after bile duct ligation in rat and survival rate after endotoxin challenge. J Gastroenterol Hepatol. 2008 Aug;23(8 Pt 1):1276-9. [Content Brief]
[4]. Chan YM, et al. Inhibition of caspases promotes long-term survival and reinnervation by axotomized spinal motoneurons of denervated muscle in newborn rats. Exp Neurol. 2003 Jun;181(2):190-203. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 3.7985 mL | 18.9926 mL | 37.9853 mL | 94.9632 mL |
| 5 mM | 0.7597 mL | 3.7985 mL | 7.5971 mL | 18.9926 mL | |
| 10 mM | 0.3799 mL | 1.8993 mL | 3.7985 mL | 9.4963 mL | |
| 15 mM | 0.2532 mL | 1.2662 mL | 2.5324 mL | 6.3309 mL | |
| 20 mM | 0.1899 mL | 0.9496 mL | 1.8993 mL | 4.7482 mL | |
| 25 mM | 0.1519 mL | 0.7597 mL | 1.5194 mL | 3.7985 mL | |
| 30 mM | 0.1266 mL | 0.6331 mL | 1.2662 mL | 3.1654 mL | |
| 40 mM | 0.0950 mL | 0.4748 mL | 0.9496 mL | 2.3741 mL | |
| 50 mM | 0.0760 mL | 0.3799 mL | 0.7597 mL | 1.8993 mL | |
| 60 mM | 0.0633 mL | 0.3165 mL | 0.6331 mL | 1.5827 mL | |
| 80 mM | 0.0475 mL | 0.2374 mL | 0.4748 mL | 1.1870 mL | |
| 100 mM | 0.0380 mL | 0.1899 mL | 0.3799 mL | 0.9496 mL |